Effectiveness of BNT162b2 (Pfizer-BioNTech) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12–18 Years — United States, July–December 2021
by from Morbidity and Mortality Weekly Report (MMWR) on (#5TS72)
This report describes how effective Pfizer-BioNTech COVID-19 vaccination was against multisystem inflammatory syndrome in children (MIS-C).